Effects of Topical Atropine on Intraocular Pressure and Myopia Progression: a Prospective Comparative Study

Overview

Journal BMC Ophthalmol

Publisher Biomed Central

Specialty Ophthalmology

Date 2016 Jul 21

PMID 27435576

Citations 20

Authors

Chia-Yi Lee

Chi-Chin Sun

Yi-Fang Lin

Ken-Kuo Lin

Affiliations

Soon will be listed here.

Abstract

Background: Myopia-related maculopathy is one of the leading causes of blindness in the world. The prevalence of myopia has been reported as high as 90 % in some Asian countries. Therefore, controlling myopia progression is an urgent public issue. The purpose of this study is to evaluate the effects of topical atropine with different concentrations on intraocular pressure measurements and myopia progression in school-aged children in Taiwan.

Methods: Fifty-six myopic children were divided into three groups: 32 children were treated with 0.125 % atropine eyedrop; 12 of them were treated with 0.25 % atropine eye drop and another 12 served as a control group. IOP, auto-refractor and manifest refraction were measured at baseline and every 3 months following treatment for one year.

Results: There were no significant differences for the mean age, gender and baseline IOPs among the three groups. During the follow up period, no significant IOP difference was found among three groups. The change between final and baseline mean IOPs also revealed no significant differences: 0.54 mmHg, -1.28 mmHg, -0.33 mmHg for the 0.125 % atropine, 0.25 % atropine and control groups. The baseline mean spherical equivalent similarly did not differ significantly among groups but the control group showed a significant myopic progression compared to the 0.125 % atropine group 6 months after treatment, and persisted for one year. The change between final and baseline mean spherical equivalents were -0.05 D, 0 D, -1.05 D for the 0.125 % atropine, 0.25 % atropine and control groups, with both atropine-treated groups showing significant myopic retardation compared to the control group.

Conclusions: Topical use of low concentration atropine for one year does not induce ocular hypertension and is effective for retarding myopic progression. However, further large scale studies with longer follow up period is necessary to validate the long term safety and efficacy.

Trial Registration: ISRCTN33002849 , 2016/01/19, retrospectively registered.

Citing Articles

Retardation of myopia by atropine regimes.

Zhu Q, Chen L, Liang J, Hu M, Xue L, Zhou G Int J Ophthalmol. 2024; 17(11):2129-2140.

PMID: 39559301 PMC: 11528274. DOI: 10.18240/ijo.2024.11.20.

Impact of atropine use for myopia control on intraocular pressure in children: A comprehensive review including postpupil dilation intraocular pressure changes.

Chen P, Hsia Y, Tsai T, Su C, Huang J, Wang T Taiwan J Ophthalmol. 2024; 14(2):179-189.

PMID: 39027062 PMC: 11254001. DOI: 10.4103/tjo.TJO-D-24-00026.

Low concentration atropine and myopia: a narrative review of the evidence for United Kingdom based practitioners.

Jawaid I, Saunders K, Hammond C, Dahlmann-Noor A, Bullimore M Eye (Lond). 2023; 38(3):434-441.

PMID: 37717107 PMC: 10858250. DOI: 10.1038/s41433-023-02718-2.

Interventions for myopia control in children: a living systematic review and network meta-analysis.

Lawrenson J, Shah R, Huntjens B, Downie L, Virgili G, Dhakal R Cochrane Database Syst Rev. 2023; 2:CD014758.

PMID: 36809645 PMC: 9933422. DOI: 10.1002/14651858.CD014758.pub2.

Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial.

Wang M, Cui C, Yu S, Liang L, Ma J, Fu A Front Pediatr. 2023; 11:1095495.

PMID: 36733432 PMC: 9888550. DOI: 10.3389/fped.2023.1095495.

References

Cooper J, Schulman E, Jamal N . Current status on the development and treatment of myopia. Optometry. 2012; 83(5):179-99. View

Wu T, Yang C, Chen H . Does atropine use increase intraocular pressure in myopic children?. Optom Vis Sci. 2011; 89(2):E161-7. DOI: 10.1097/OPX.0b013e31823ac4c1. View

Lachkar Y, Bouassida W . Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol. 2007; 18(2):129-33. DOI: 10.1097/ICU.0b013e32808738d5. View

Harris L . Cycloplegic-induced intraocular pressure elevations a study of normal and open-angle glaucomatous eyes. Arch Ophthalmol. 1968; 79(3):242-6. DOI: 10.1001/archopht.1968.03850040244004. View

Chou A, Shih Y, Ho T, Lin L . The effectiveness of 0.5% atropine in controlling high myopia in children. J Ocul Pharmacol Ther. 1997; 13(1):61-7. DOI: 10.1089/jop.1997.13.61. View

Jensen H . Myopia progression in young school children and intraocular pressure. Doc Ophthalmol. 1992; 82(3):249-55. DOI: 10.1007/BF00160772. View

Chia A, Chua W, Cheung Y, Wong W, Lingham A, Fong A . Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2011; 119(2):347-54. DOI: 10.1016/j.ophtha.2011.07.031. View

Wilson M, Lee G, Chandra A, Kane G . Central anticholinergic syndrome following dobutamine-atropine stress echocardiography. Echocardiography. 2011; 28(10):E205-6. DOI: 10.1111/j.1540-8175.2011.01509.x. View

Guo Y, Lin H, Lin L, Cheng C . Self-reported myopia in Taiwan: 2005 Taiwan National Health Interview Survey. Eye (Lond). 2012; 26(5):684-9. PMC: 3351071. DOI: 10.1038/eye.2012.9. View

10.

Shih Y, Chen C, Chou A, Ho T, Lin L, Hung P . Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther. 1999; 15(1):85-90. DOI: 10.1089/jop.1999.15.85. View

11.

Greenstein S, Abramson D, Pitts 3rd W . Systemic atropine and glaucoma. Bull N Y Acad Med. 1984; 60(10):961-8. PMC: 1911809. View

12.

Jensen H . Timolol maleate in the control of myopia. A preliminary report. Acta Ophthalmol Suppl (1985). 1988; 185:128-9. DOI: 10.1111/j.1755-3768.1988.tb02686.x. View

13.

Herring I, Pickett J, Champagne E, Troy G, Marini M . Effect of topical 1% atropine sulfate on intraocular pressure in normal horses. Vet Ophthalmol. 2001; 3(2-3):139-143. DOI: 10.1046/j.1463-5224.2000.00134.x. View

14.

Stadtbaumer K, Frommlet F, Nell B . Effects of mydriatics on intraocular pressure and pupil size in the normal feline eye. Vet Ophthalmol. 2006; 9(4):233-7. DOI: 10.1111/j.1463-5224.2006.00474.x. View

15.

Wen G, Tarczy-Hornoch K, McKean-Cowdin R, Cotter S, Borchert M, Lin J . Prevalence of myopia, hyperopia, and astigmatism in non-Hispanic white and Asian children: multi-ethnic pediatric eye disease study. Ophthalmology. 2013; 120(10):2109-16. PMC: 3902090. DOI: 10.1016/j.ophtha.2013.06.039. View

16.

Gwiazda J . Treatment options for myopia. Optom Vis Sci. 2009; 86(6):624-8. PMC: 2729053. DOI: 10.1097/OPX.0b013e3181a6a225. View

17.

Fan D, Lam D, Chan C, Fan A, Cheung E, Rao S . Topical atropine in retarding myopic progression and axial length growth in children with moderate to severe myopia: a pilot study. Jpn J Ophthalmol. 2007; 51(1):27-33. DOI: 10.1007/s10384-006-0380-7. View

18.

Wallman J . Nature and nurture of myopia. Nature. 1994; 371(6494):201-2. DOI: 10.1038/371201a0. View

19.

Li S, Wu S, Kang M, Liu Y, Jia S, Li S . Atropine slows myopia progression more in Asian than white children by meta-analysis. Optom Vis Sci. 2014; 91(3):342-50. DOI: 10.1097/OPX.0000000000000178. View

20.

Ganesan P, Wildsoet C . Pharmaceutical intervention for myopia control. Expert Rev Ophthalmol. 2011; 5(6):759-787. PMC: 3023964. DOI: 10.1586/eop.10.67. View